Meeting
2014 ASCO Annual Meeting
European leukemia net (ELN) 2013 response categories: Impact on clinical outcomes across four frontline tyrosine kinase inhibitor (TKI) modalities in chronic phase CML.
Authors
Preetesh Jain
The University of Texas MD Anderson Cancer Center, Houston, TX
Preetesh Jain , Hagop M. Kantarjian , Dasarathula Jyothsna , Alfonso Quintas-Cardama , Elias Jabbour , Marylou Cardenas-Turanzas , Sara Dellasala , Sherry Pierce , Farhad Ravandi , Susan Mary O'Brien , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7089)
DOI
10.1200/jco.2014.32.15_suppl.7089
Abstract #
7089
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.
First Author: Tony Varughese
Poster
2019 ASCO Annual Meeting
Risk of QTc interval prolongation among cancer patients treated with tyrosine kinase inhibitors.
First Author: Anan Abdelmoti Abu Rmilah Jr.
Poster
2018 ASCO Annual Meeting
Relapse prevention with second generation tyrosine kinase inhibitors for Ph+ve acute leukemia after allogenic stem cell transplantation.
First Author: Faiz K. Anwer
Poster
2016 ASCO Annual Meeting
Survival outcomes of sustained MR4.5 in patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKI).
First Author: Boyu Hu